Loading...
Novel agents in development for advanced non-small cell lung cancer
The identification of EGFR mutations and ALK rearrangements in nonsmall cell lung cancer (NSCLC) has led to the rapid development of targeted therapies and significant changes in the treatment paradigm. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and crizotinib are now...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206610/ https://ncbi.nlm.nih.gov/pubmed/25342991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014532510 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|